BoneSupport AB is a Swedish biotech company active at the Ideon Science Park in the university town of Lund in Skåne, Sweden, founded in 1999 by Lars Lidgren, Professor of Orthopedic Surgery and Academic Head of Department at Lund University Hospital in Sweden which is a member of the ISOC group of global leading orthopaedic centers. The company has been funded with more than SEK 500 million in venture capital from inter alia HealthCap, Lundbeck foundation and Industrifonden, making it one of the largest ventures in the Swedish medical technologies industry.
Cerament is a synthetic injectable osteoconductive biomaterial, which actively promotes bone healing and is utilized as a bone substitute, when bone grafting is needed. Full remodeling to healthy bone occurs between 6 to 12 months.
Cerament is used for the treatment of fragility fractures caused by Osteoporosis, to fill bone voids or gaps caused by trauma or orthopedic surgical procedures for i.e. benign tumors, and for augmentation of fracture repair. Cerament can be loaded with antibiotics like Gentamicin (Cerament with gentamicin is not FDA approved), thereby protecting bone healing in patients with bone infections (osteomyelitis)
In September 2012, BoneSupport entered a distribution agreement with the major medical device manufacturer Biomet who have exclusive distribution rights of the Cerament bone void filler product range in the United States of America and Canada. This agreement is expected to accelerate the usage of Bonesupport’s bone void filler (Cerament) product line in orthopaedic operations.
- BoneSupport AB annual report 2013
- Bone Healing Using a Bi-Phasic Ceramic Bone Substitute Demonstrated in Human Vertebroplasty and with Histology in a Rabbit Cancellous Bone Defect Model. H.P. Hatten Jr, J. Voor. Interventional Neuroradiology 18: 105-113, 2012
- Osteotomy Of Distal Radius Fracture Malunion Using a Fast Remodeling Bone Substitute Consisting of Calcium Sulphate and Calcium Phosphate. Abramo A, Geijer M, Kopylov P, Tägil M. J of Biomed Materials Research (B) Nov 2009 281-286